ASH 2019 | Cost-effectiveness of 12-month VenG for CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses a study estimating the cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab (VenG) for the first-line treatment of chronic lymphocytic leukemia (CLL) in the United States. A 12-month fixed-duration treatment with VenG appears to be a cost-effective standard therapy for CLL patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up